Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

NCT05782127 | Active Not Recruiting Phase 1 DMC

• 2 other identifiers: GFM-ONUVEN-MDS2022-000634-41
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 25

Brief Summary

This phase I/II open-label, dose-finding, multi-center study will assess safety and primary efficacy of Onureg and Venetoclax combination, to define the optimal biological dose and optimal treatment duration of Onureg to be used along with Venetoclax for further studies in previously untreated patients with higher-risk myelodysplastic syndromes (HR-MDS) not eligible to transplant.

Conditions

Untreated Myelodysplastic Syndrome

Keywords

MDS; Oral Azacitidine; Venetoclax

Outcome Measures

Primary Outcomes (2)

• Dose-limiting toxicity

  Dose-limiting toxicities according to CTCAE (common terminology criteria for adverses events) 5.0 occurring within the first cycle of treatment

  at day 28 of cycle 1

• Overall response

  Overall response measured after the first cycle of treatment according to modified IWG-MDS (International Working Group-Myelodysplastic Syndromes) 2006

  at day 28 of cycle 1

Secondary Outcomes (15)

• Best response

  after 6 cycles of treatment (each cycle is 28 days)

• Hematological improvement

  at end of treatment (an average of 4 years)

• Time to response

  at end of treatment (an average of 4 years)

• Duration of response

  at end of study (an average of 5 years)

• Progression to acute myeloid leukemia (AML)

  at end of treatment (an average of 4 years)

Other Outcomes (2)

• Exploratory endpoints by NGS

  end of study (an average of 5 years)

• MRD response rate

  end of study (an average of 5 years)

Study Arms (1)

Onureg + Venetoclax

EXPERIMENTAL

Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles. Venetoclax will be administered orally at 400 mg once daily for 14 consecutive days on days 1 to 14, beginning on Day 1 of repeated 28-day cycles. Patients will be treated up to 4 cycles and for a maximum of 24 cycles.

Drug: Onureg + Venetoclax

Interventions

Onureg + Venetoclax DRUG

Combination of Onureg and Venetoclax

Also known as: CC-486 + ABT-199

Onureg + Venetoclax

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must understand and voluntarily sign and date an ICF indicating the investigational nature of the study, approved by an independent EC/IRB, prior to the initiation of any screening or study-specific procedures.
• Age ≥ 18 years at the date of signing the ICF.
• Diagnosis of MDS according to the 2016 WHO classification (13) (Appendix 1), with presence of \< 20% bone marrow blasts per bone marrow aspirate at screening, confirmed by local investigator with HR-MDS, based on the revised International Prognostic Scoring System (IPSS-R) \>3 (intermediate, high or very high) (14) (Appendix 2) and a blast percentage of 5 or more.
• Previously untreated HR-MDS: no prior therapy for MDS with any hypomethylating agents (azacitidine or decitabine), chemotherapy, allo-Hematopoietic Stem Cell Transplantation (HSCT) or experimental agent. All other treatments are not considered prior therapy.
• Not immediately eligible for allo-HSCT or intensive chemotherapy at the time of screening due to individual clinical factors such as age, comorbidities and performance status, donor availability.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• Adequate liver functions as demonstrated by:
• Serum alanine transaminase (ALT) \< 3.0 × upper limit of normal \[ULN\];
• Serum aspartate transaminase (AST) \< 3.0 × ULN;
• Serum total bilirubin ≤ 2.0 × ULN (except in the setting of isolated Gilbert syndrome, where participants may only be included with total bilirubin ≤ 3.0 x ULN)
• Adequate renal function with calculated creatinine clearance ≥ 40 mL/min/1.73 m² (estimation based on Modification of Diet in Renal Disease (MDRD) formula or CKD-EPI, by local laboratory).
• Participant is able to communicate with the investigator, and has the ability to comply with the requirements of the study procedures, available for regular blood sampling, study related assessments, including bone marrow aspirates and appropriate clinical management at the treating institution for the duration of the study.
• Females of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). FCBP must agree to undergo medically supervised pregnancy test prior to starting study drug, during the course of the study, and after end of study therapy:
• Have one negative pregnancy test as verified by the Investigator prior to starting study therapy. The first pregnancy test will be performed at screening (within 3 days prior to first study drug administration), and a negative urinary test before starting all subsequent cycles. This applies even if the participant practices true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective contraception without interruption, 28 days prior to starting investigational product, during the study therapy (including dose interruptions), and for 6 months after last dose of Onureg, or at least 1 month after the last dose of venetoclax, whichever is later or longer if required by local regulations.
• Female patients are either post-menopausal, free from menses for \> 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agree to abstain from becoming pregnant throughout the study, starting with Visit 1. Females of reproductive potential as well as fertile men and their partners who are female of reproductive potential must agree to abstain from sexual intercourse or to use two highly effective forms of contraception from the time of giving informed consent, during the study and for 6 months (females and males) following the last dose of treatment.

You may not qualify if:

• Previous treatment for MDS, any approved or investigational antineoplastic agents or radiotherapy.
• Previous diagnosis of:
• MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)
• MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.
• Participant has an active, uncontrolled systemic fungal, bacterial, or viral infection. The participant should be afebrile and off antibiotics for at least 72 hours and off antifungals for 7 days. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the patient at a higher risk of receiving investigational treatment.
• History of clinically significant medical conditions, laboratory abnormality, psychiatric illness or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study drug or predisposes the participant to high risk of noncompliance with the protocol.
• History of active malignancy within the past year prior to screening, with the exception of:
• Adequately treated carcinoma in situ of the uterine cervix
• Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
• Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy.
• Patients with ongoing horomonotherapy could be included.
• Participant has received strong or moderate CYP3A inhibitors or inducers or p-gp inhibitors within 7 days prior to initiation of study treatment with prolonged treatment required without therapeutic alternatives. Azols are the only exception and may be permitted after cycle 1 at investigator's discretion and will result in venetoclax dose reduction.
• Consumption of grapefruit products, Seville oranges or starfruit within 3 days prior to first dose of venetoclax.
• Received live attenuated vaccines prior to initiation of study treatment.
• History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.

Sponsors & Collaborators

• Groupe Francophone des Myelodysplasies: lead
• Bristol-Myers Squibb: collaborator
• AbbVie: collaborator

Study Sites (25)

CHU d'Amiens Picardie - Site sud

Amiens, 80054, France

Location

CHU d'Angers

Angers, 49033, France

Location

Hôpital Avicenne

Bobigny, 93009, France

Location

Hôpital privé Sévigné

Cesson-Sévigné, 35510, France

Location

CH Annecy Genevois

Épagny, 74370, France

Location

CHU de Grenoble

Grenoble, 38043, France

Location

CH Le Mans

Le Mans, 72037, France

Location

Hôpital Saint Vincent de Paul

Lille, 59020, France

Location

CHU de Limoges - Hôpital Dupuytren

Limoges, 87042, France

Location

CH Lyon sud

Lyon, 69495, France

Location

Institut Paoli Calmettes

Marseille, 13009, France

Location

CHI Mont-de-Marsan

Mont-de-Marsan, 40000, France

Location

CHU Saint Eloi

Montpellier, 34295, France

Location

CHU Hôtel Dieu

Nantes, 44093, France

Location

Hôpital Archet 1

Nice, 06200, France

Location

CHU Nîmes - Institut de Cancérologie du Gard

Nîmes, 30029 cedex 9, France

Location

Hôpital Saint Louis

Paris, 75010, France

Location

Hôpital Cochin

Paris, 75014, France

Location

CHU de Haut-Lévèque

Pessac, 33604, France

Location

CHU de Poitiers

Poitiers, 86021, France

Location

Centre Henri Becquerel

Rouen, 76038, France

Location

IUCT Oncopole

Toulouse, 31059, France

Location

CHU de Tours - Hôpital Bretonneau

Tours, 37000, France

Location

CH Valence

Valence, 26000, France

Location

Hôpital Brabois

Vandœuvre-lès-Nancy, 54500, France

Location

MeSH Terms

Interventions

venetoclax; cc-486

Study Officials

• Colombe SAILLARD, MD

  Institut Paoli-Calmettes

  PRINCIPAL INVESTIGATOR

• Norbert VEY, MD/PhD

  Institut Paoli-Calmettes

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 23, 2023
• First Posted: March 23, 2023
• Study Start: December 6, 2023
• Primary Completion: December 1, 2025
• Study Completion (Estimated): November 1, 2028
• Last Updated: March 13, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (25)